Crinetics (CRNX) PT Raised to $56 at Jones Trading

Go back to Crinetics (CRNX) PT Raised to $56 at Jones Trading

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

March 19, 2024 6:00 AM EDT

56% of Participants on Paltusotine Achieved IGF-1 1.0 xULN vs. 5% on Placebo (p... More